Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease

Inclusion criteria; Patients diagnosed as Alzheimer's Disease by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Patients diagnosed as mild or moderate Alzheimer's Disease, applicable to Functional Assessment Staging (FAST) score 4 or 5. Exclusion criteria; Patients who used Aricept within 3 months prior to dosing. Patients registered this survey before. Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.